October 3, 2012
Today, Brenton Flynn looks at Abbott Labs' favorable news for a key drug but cautions that the news should be taken with a grain of salt. When Abbott Labs spins itself off to become two companies, this drug will make up a hefty portion of the revenue for AbbVie, just in time for it to fall off the patent cliff.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.